此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cryotherapy for Bronchoscopic Management of Central Airway Obstruction: Clinical Experience at Assiut University Hospital.

2026年11月16日 更新者:Ebtesam Adel Hammad Askar、Assiut University

The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

研究概览

详细说明

Introduction:

Central airway obstruction (CAO) is defined as significant narrowing of the trachea, main stem bronchi or the bronchus intermedius, and occurs in a wide variety of airway disorders, including endobronchial tumors, post-intubation and post-tracheostomy stenosis, post-infectious stenosis, granulation tissue, tracheomalacia, and foreign body obstruction . It is associated with a poor prognosis and impaired quality of life, even when the underlying cause is benign.

Therapeutic bronchoscopy can improve symptoms, quality of life, and survival in patients with CAO, and the current American College of Chest Physicians guideline supports a multimodality approach that includes tissue debridement, ablation, dilation, and stent placement according to the underlying disease . Recent evidence shows substantial improvements in breathlessness and quality of life after therapeutic airway interventions, with a low complication rate in a large long-term series.

Bronchoscopic cryotherapy is a pragmatic modality for recanalization of CAO that can be delivered through a flexible bronchoscope under moderate sedation, achieving more than partial airway patency in about 90% of sessions in an 11-year single-center cohort, although bleeding remains the main concern [7]. Its usefulness has also been shown in tumor-like endobronchial tuberculosis and, with the spray technique, in a prospective registry of central airway diseases . In Egypt, a single-center study reported that cryotherapy was safe and improved clinical scores, pulmonary function, and quality of life in patients with CAO of different etiologies . Evidence regarding bronchoscopic cryotherapy for CAO remains limited in our region despite its increasing clinical utilization. This study aims to assess the feasibility, safety, and clinical outcomes of bronchoscopic cryotherapy for CAO within the constraints of a resource-limited healthcare environment and evaluating our institutional experience at Assiut University Hospital.

  • The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

  • Type of the study: Prospective Interventional Study.

  • Study Group: The study will include patients diagnosed with central airway obstruction (CAO) and fit for bronchoscopy.

  • Study Setting: Respiratory bronchoscopy unit, Assuit University Hospital. Study subjects: All adult patients diagnosed with central airway obstruction(CAO) and fit for bronchoscopic intervention will be eligible.

    a. Inclusion criteria:

    • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
    • b. Exclusion criteria:
    • Patients with coagulopathy (INR > 1.5).
    • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
    • Severe pulmonary hypertension (PASP > 55 mmHg).
    • Hemodynamic instability.
    • Lung collapse > 2 months duration. c.Sample size calculation:

The sample size was calculated using Epi Info™️ version 7 software based on the following assumptions:

The primary outcome variable was the successful airway recanalization rate. Based on a previous study by Hussein et al. (2026), the overall successful recanalization rate (complete and partial) was 96%. Assuming an expected proportion of 96%, a confidence level of 90%, and a confidence limit (margin of error) of 5%, the minimum required sample size was estimated to be 42.

  • Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):

Baseline Evaluation

Prior to the intervention, all candidates will undergo:

  • Clinical Assessment: Detailed history taking, physical examination, and dyspnea assessment using the modified Medical Research Council (mMRC) scale, while cough and hemoptysis were evaluated using the Walsh cough score and the Morice hemoptysis severity score, respectively.

  • Laboratory Tests: CBC, liver/kidney functions, coagulation profile, fasting blood glucose, and Arterial Blood Gases (ABG)

  • Radiological Imaging: Plain Chest X-ray (PA view) and CT chest to evaluate the site and extent of the obstruction.

  • Functional assessment : ABG and pulmonary function test pre and post procedure. Intervention Protocol (Therapeutic Bronchoscopy)

    1. General Preparation

  • Anesthesia: This procedure will be performed under local anesthesia .

  • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.

  • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.

  • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

    1. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia in one or two sessions, each lasting 30-60 min. The cryo¬probe will be inserted through the bronchoscope biopsy channel which is positioned approximately 10 mm above the lesion and the probe is in direct contact to the lesion. The lesion will be frozen for 20-60 s/cycle for three cycles to devascularize the tumor, after which the bronchoscope and cryoprobe will be removed together with adherent tissue.

IV. Follow-up Parameters

  • Immediate (Post-procedure): Chest X-ray within 2 hours to exclude pneumothorax.
  • Short-term: Monitoring for peri-procedural complications within the first 24 hours Complications were classified as minor (e.g., self-limited bleeding, transient hypoxemia, mild pneumomediastinum not requiring invasive intervention) or major (e.g., life-threatening bleeding, respiratory failure requiring ventilatory support, pneumothorax requiring chest tube insertion).This classification was conceptually aligned with the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  • Bronchoscopic grading of bleeding severity; Grade 1: Bleeding requiring suctioning for less than 1 minute. Grade 2: Bleeding requiring suctioning for more than 1 minute, repeated wedging of the bronchoscope, or topical haemostatic agents.

Grade 3: Bleeding requiring selective intubation with an endotracheal tube or balloon/bronchial blocker for less than 20 minutes, or premature termination of the procedure.

Grade 4: Persistent selective intubation for more than 20 minutes, ICU admission, transfusion, bronchial artery embolisation, or resuscitation.

- Long-term: Patients will be followed for up to 3 months post-procedure, including:

  • Clinical evaluation ;

    - Quality of life (SF-36),symptoms(cough,dyspnea,hemoptysis).

  • Functional Evaluation ; ABG and spirometry.

  • Bronchoscopic evaluation (to check for re-obstruction)if clinically indicated.

  • Radiological evaluation (CT or Chest X-ray).

    • Research outcome measures:

      1. Primary (main):

Technical efficacy: Percentage of patients achieving successful airway recanalization following bronchoscopic cryotherapy, according to the Freitag et al & Hussein et al :

  1. Complete canalization: ≥90% restoration of airway lumen
  2. Partial canalization: 50-89% restoration.
  3. Failed canalization: <50% restoration or inability to proceed due to complications

b. Secondary (subsidiary):

  1. Symptomatic Improvement: Changes in dyspnea (mMRC scale),cough and hemoptysis score evaluated at short-term and at the 3-month follow-up.
  2. Safety Profile: incidence of minor and major peri-procedural complications within 24 hours, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  3. Long-term Airway Patency: Rate of re-obstruction and CAO-related re-hospitalization during the 3-month follow-up period.
  4. Overall Survival: Estimation of the 1-year overall survival (OS) rate post-intervention

研究类型

介入性

注册 (估计的)

42

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Ebtesam Adel Hammad Askar, Assistant Lecturer
  • 电话号码:+2001012089691
  • 邮箱:ebtesam6569@gmail.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

• Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy.

Exclusion Criteria:

  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:All adult patients diagnosed with CAO and fit for bronchoscopic intervention

Study subjects: All adult patients diagnosed with CAO and fit for bronchoscopic intervention will be eligible.

a. Inclusion criteria:

  • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
  • b. Exclusion criteria:
  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration.

Intervention Protocol (Therapeutic Bronchoscopy)

  1. General Preparation

    • Anesthesia: This procedure will be performed under local anesthesia .
    • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.
    • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.
    • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

3. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
percentage of patients achieving central airway recanalization.
大体时间:Follow up after 3 months

Successful airway recanalization following therapeutic bronchoscopic cryotherapy for central airway obstruction (CAO), defined according to the Freitag et al. and Hussein et al. criteria.

Follow up after 3 months

次要结果测量

结果测量
措施说明
大体时间
Change in Dyspnea Severity.
大体时间:baseline and at 3 months follow up

Change from baseline in dyspnea evaluated using the modified Medical Research Council (mMRC) dyspnea scale (score range 0 to 4, where higher scores indicate worse dyspnea).

baseline and at 3 months follow up
Change in Cough Score
大体时间:baseline and at 3 months follow up period

Change from baseline according to walsh cough score

baseline and at 3 months follow up period
Change in Hemoptysis Score
大体时间:baseline and at 3 months follow up period

Change from baseline according to morice hemoptysis score

baseline and at 3 months follow up period
Incidence of Minor and Major Peri-procedural Complications
大体时间:Within 24 hours post-procedure

Number of participants with treatment-related adverse events and complications, categorized by severity using the Common Terminology Criteria for Adverse Events (CTCAE) framework.

Within 24 hours post-procedure
Rate of Airway Re-obstruction and CAO-related Re-hospitalization
大体时间:up to 3 months

Percentage of patients experiencing symptomatic airway re-obstruction or requiring re-hospitalization related to central airway obstruction (CAO).

up to 3 months
1-Year Overall Survival (OS) Rate
大体时间:1 year

Percentage of participants alive at 1 year following the bronchoscopic cryotherapy intervention.

1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月10日

初级完成 (估计的)

2027年11月10日

研究完成 (估计的)

2028年11月10日

研究注册日期

首次提交

2026年11月3日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • AssiutU-med-2026

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅